Q-omics provides the consensus-scored RPL23AP17 profile across patient tissues and cancer cell-line models. RPL23AP17 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RPL23AP17 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, RPL23AP17 RNA expression shows 8,341 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where RPL23AP17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP17 survival associations across molecular data types. RPL23AP17 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP17 RNA expression–survival associations across cancer types. High RPL23AP17 expression shows unfavorable associations in TGCT, DLBC and MESO, but favorable associations in LUAD, CESC and LAML. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify LUAD as the clearest survival context for RPL23AP17 RNA expression.
This table summarizes RPL23AP17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP17 shows lower tumor expression in READ and KICH and higher tumor expression in KIRC, HNSC and COAD. The KIRC box plot shows higher RPL23AP17 RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .003).
This table shows molecular features associated with RPL23AP17 in patient tissues and cancer cell lines. In patient samples, RPL23AP17 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
